AMAG Pharmaceuticals Inc

AMAG Pharmaceuticals — FY2018 Earnings Presentation

29 slides from AMAG Pharmaceuticals's earnings presentation, Feb 7, 2019

  1. Slide 1: AMAG Pharmaceuticals 2018 Financial Results & Company Update

    AMAG Pharmaceuticals 2018 Financial Results & Company Update February 7, 2019 © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward‐looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, the

  3. Slide 3: Agenda

    Agenda 1 2018 Accomplishments 2 Commercial Product Portfolio Update 3 Development Product Portfolio Update – Focus on Ciraparantag 4 Financial Overview 5 Q&A © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 3

  4. Slide 4: 2018 Accomplishments

    2018 Accomplishments Intrarosa® (prasterone) .  Established strong healthcare provider support . Initiated direct-to-consumer campaign VyleesiTM (bremelanotide) . FDA acceptance of new drug application (NDA)  . Initiated frequent dosing study in healthy volunteers Makena® (hydroxyprogesterone capr

  5. Slide 5: Achieved 2018 Financial Objectives

    Achieved 2018 Financial Objectives Increased financial guidance three times throughout 2018 Preliminary Results ($M) 2018 Issued Guidance1,3 Issued in January 2019 January 2018 May 2018 August 2018 November 2018 FY 2018 Total revenue $380 - $440 $420 - $460 $450 - $490 $470 - $490 $471 - $476 Operat

  6. Slide 6: Historical Value Drivers

    Historical Value Drivers HISTORICAL Value of AMAG © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 6

  7. Slide 7: Feraheme Continues to Grow with Expanded Label

    Feraheme Continues to Grow with Expanded Label Annual Feraheme Revenue ($M) Feraheme Growth • Strong execution with expanded lDA label drove 27% significant volume increases in 2018 – Performance-based contracting drove volume, with stable annual price • Q4-2018 average market share rose to 16.6%, c

  8. Slide 8: Continued Strong Conversion from Makena IM to SC Auto-injector

    Continued Strong Conversion from Makena IM to SC Auto-injector Annual Makena Revenue ($M) Makena Stability • Q4-2018 SC auto-injector – Achieved $35M revenue • Ex-factory sales impacted by a reduction in channel inventory levels at year end due to temporary supply constraints, which are now resolved

  9. Slide 9: Significant Shareholder Value at AMAG

    Significant Shareholder Value at AMAG Historical Value Drivers Fund Future Value Drivers ciraparantag AMAG-423 Fundingfunding HISTORICAL Value of AMAG FUTURE Value of AMAG Historical Value Drivers Fund Future Value Drivers © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 9

  10. Slide 10: Intrarosa HCP Prescribing and Market Share Continue to Increase

    Intrarosa HCP Prescribing and Market Share Continue to Increase Direct-to-Consumer (DTC) campaign demonstrating strong patient engagement Annual Intrarosa Revenue ($M) Intrarosa Growth • Strong prescription trends continue2 – 13.6% overall TRx market growth in 2018 – 159,000 TRxs in 2018 – 13,000+ p

  11. Slide 11: Accessing the 90% of Women Who are Not Being Treated with Rx

    Accessing the 90% of Women Who are Not Being Treated with Rx 2019 Branded consumer campaign resulting 5 in patients asking for Intrarosa Increase HCP prescribing and make 4 Intrarosa the 1st choice treatment 2018 3 Educate with unbranded condition awareness campaign Create affordable access 2 for al

  12. Slide 12: AMAG's Growing Innovative Pipeline

    AMAG's Growing Innovative Pipeline Approved/ Phase 1 Phase 2 Phase 3 Regulatory Review Marketed Ciraparantag Anticoagulant reversal agent (potential for orphan drug designation) Treatment of iron deficiency anemia H E M A T O L O G Y AMAG-423 Treatment of severe preeclampsia Digoxin Immune (orphan d

  13. Slide 13: AMAG Product Development Milestone Calendar

    AMAG Product Development Milestone Calendar 1H-2019 2H-2019 1H-2020 2H-2020 1H-2021 2H-2021 June 23 Potential Vyleesi PDUFA date commercial launch 423 - Target complete enrollment in Phase 2b/3a trial Topline data NDA submission Potential FDA approval AMAG End of Phase 2 Complete Phase 1 Closed Pero

  14. Slide 14: Novel Oral Anticoagulant (NOAC) Use Growing

    Novel Oral Anticoagulant (NOAC) Use Growing • Anticoagulants (often referred to as blood thinners) reduce the ability of the blood to form clots – Prevention of stroke in patients with nonvalvular atrial fibrillation – Prevention and treatment of deep vein thrombosis and pulmonary embolism – Use of

  15. Slide 15: Ciraparantag: Differentiated Anticoagulation Reversal Therapy

    Ciraparantag: Differentiated Anticoagulation Reversal Therapy Well suited for use in emergency room setting Storage & Duration Prothrombotic Reversal Agent Dosing Preparation of Action Signal Praxbind® • Requires storage at • One treatment given as 2 • Sustained effect over • No prothrombotic o o o

  16. Slide 16: Action of Anticoagulants and Ciraparantag in the Blood Clotting Cascade

    Action of Anticoagulants and Ciraparantag in the Blood Clotting Cascade Whole Blood Clotting Time (WBCT) is the most clinically relevant measure in healthy volunteers F XII WBCT is currently a manual measure of the time it takes Clotting Cascade for blood to clot – clinically relevant physiologic ou

  17. Slide 17: Phase 2b Study: Reversal of Xarelto

    Phase 2b Study: Reversal of Xarelto® Ongoing study in healthy subjects; high dose group demonstrates 100% response rate Ciraparantag or placebo dose 0.0% Baseline & Xarelto® dose WBCT reversed to within 10% n n n n 1 of baseline within 30 minutes Placebo Ciraparantag 60 mg Ciraparantag 120 mg Cirapa

  18. Slide 18: Favorable Safety Profile of Ciraparantag

    Favorable Safety Profile of Ciraparantag Ciraparantag was well tolerated in over 250 subjects dosed in Phase 1/2 clinical studies to date • Across Phase 1/2 clinical studies (5 completed studies, 2 ongoing studies) to date – Over 250 healthy adult subjects have received ciraparantag; doses ranged fr

  19. Slide 19: Ciraparantag Path to Approval

    Ciraparantag Path to Approval 1H-2019 2H-2019 1H-2020 2H-2020 1H-2021 2H-2021 End of Phase 2 Complete Phase 1 Closed Perosphere NDA submission Potential FDA approval meeting with FDA; 3a trials; acquisition Initiate Phase 3a trials announce topline data Apply for orphan Initiate and breakthrough Pha

  20. Slide 20: Financial Overview

    Financial Overview 20

  21. Slide 21: 2018 Financial Results within Guidance Range

    2018 Financial Results within Guidance Range For 12-months ended December 311 $M 2018 2017 • Makena decline due to IM generic competition and supply Makena $322.3 $387.2 constraints; partially offset by success of auto-injector launch in Q2-2018 and AGx Feraheme/MuGard 135.4 106.7 Intrarosa 16.2 1.8

  22. Slide 22: Reaffirming 2019 Financial Guidance

    Reaffirming 2019 Financial Guidance Published on January 7, 2019 Key inputs and drivers of financial guidance • Spending includes increase in R&D – Completion of Phase 2 development of ciraparantag, initiation ($M) 2019 Financial Guidance1 of Phase 3a trial – Targeting full enrollment of AMAG-423 Ph

  23. Slide 23: Strong Balance Sheet

    Strong Balance Sheet ($M) 12/31/18 12/31/17 Cash, cash equivalents and investments $3941 $329 Short-term debt: Convertible senior notes (2.5%) due Feb. 2019 $ 21 $ 21 Long-term debt: Convertible senior notes (3.25%) due 2022 $320 $320 Senior notes (7.875%) due 2023 $ 0 $475 1 $394M cash balance does

  24. Slide 24: Strong Execution Transforms Company Profile in 2019

    Strong Execution Transforms Company Profile in 2019 2019 Goals  Expand use of Makena SC auto-injector  Drive Feraheme growth  Continue successful Intrarosa direct-to-consumer campaign  Submit Vyleesi frequent-dosing study data  Prepare for Vyleesi commercial launch in 2H-2019  Target full enro

  25. Slide 25: AMAG Pharmaceuticals Q&A

    AMAG Pharmaceuticals Q&A © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 25

  26. Slide 26: Appendix

    Appendix 26

  27. Slide 27: Reconciliation of GAAP to Non-GAAP Financial Results

    Reconciliation of GAAP to Non-GAAP Financial Results Preliminary Results Issued in January 2019 $M 2018 2017 2018 GAAP operating income (loss) ($47.0) ($303.8) ($55) - ($45) Depreciation and intangible asset amortization 160.0 131.6 161 Non-cash inventory step-up adjustments 3.7 2.2 4 Stock-based co

  28. Slide 28: Reconciliation of GAAP to Non-GAAP Financial Guidance

    Reconciliation of GAAP to Non-GAAP Financial Guidance Guidance Issued ($M) January 2018 May 2018 August 2018 November 2018 January 2019 GAAP operating loss ($169) – ($139) ($149) – ($129) ($75) - ($55) ($72) - ($62) ($131) – ($101) Depreciation & intangible asset amortization 179 179 174 177 43 Stoc

  29. Slide 29: AMAG Pharmaceuticals 2018 Financial Results & Company Update

    AMAG Pharmaceuticals 2018 Financial Results & Company Update February 7, 2019 © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 29

Amag Pharmaceuticals — FY2018 Earnings Presentation on 6ix